Business Segments Amplia Therapeutics Limited
Stocks
ATX
AU0000023822
Biotechnology & Medical Research
|
Market Closed -
Australian S.E.
02:10:15 2026-08-19 EDT
|
5-day change | 1st Jan Change | ||
| 0.1450 AUD | -6.45% |
|
-3.33% | -3.33% |
Sales 2026 by Business Segment
Sales 2026 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biopharmaceutical Sector | 1.98M | 1.19M | 4.45M | 3.78M | 4.79M | |||||
Total Assets | 24.48M | 18.68M | 14.85M | 22.94M | 41.44M | |||||
Interest Expense | -1.15K | -53.85K | -78.48K | -55.88K | -17.37K | |||||
CAPEX | -14.4K | -17.63K | -2.23K | -2.07K | -33.3K | |||||
EBT | -3.64M | -6.24M | -4.5M | -6.57M | -7.71M | |||||
D&A | 3.21K | 73.37K | 86.15K | 85.63K | 92.14K | |||||
Operating Income | -3.64M | -6.19M | -4.42M | -6.52M | -7.69M | |||||
Net Income | -3.64M | -6.24M | -4.5M | -6.57M | -7.71M |
Geographical Revenue Distribution History
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Australia | 1.98M | 1.19M | 4.45M | 3.78M | 4.79M | |||||
Total Assets | 24.48M | 18.68M | 14.85M | 22.94M | 41.44M | |||||
Interest Expense | -1.15K | -53.85K | -78.48K | -55.88K | -17.37K | |||||
D&A | 3.21K | 73.37K | 86.15K | 85.63K | 92.14K | |||||
CAPEX | -14.4K | -17.63K | -2.23K | -2.07K | -33.3K | |||||
Net Income | -3.64M | -6.24M | -4.5M | -6.57M | -7.71M | |||||
EBT | -3.64M | -6.24M | -4.5M | -6.57M | -7.71M | |||||
Operating Income | -3.64M | -6.19M | -4.42M | -6.52M | -7.69M | |||||
New Zealand | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
- Stock Market
- Stocks
- ATX Stock
- Financials Amplia Therapeutics Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
